Please assess the completion status of the following clinical trial:

Trial Title: Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>/=18 and \< 40 years old;~* BMI between 18 and 30 kg/m2;~* less than 3 previous completed cycles;~* both ovaries present;~* regular menstrual cycle of 25-35 days;~* infertility attributable to a tubal factor, American Fertility Society grade I or II endometriosis, male factor or unexplained factor.~* within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through hysterosalpingogram, sonohystrogram or hysteroscopic examination;~* basal FSH level less than 10 IU/L;~* criteria for hCG administration fulfilled (at least 2 follicles with a diameter of 16 mm or more, with acceptable serum E2 concentration).~* a male partner with semen analysis within the past 6 months showing acceptable values of seminal parameters, defined as \> 3x10 exp 6 spermatozoa/ml;~* qualified to receive 150 - 300 IU FSH as starting dose.~Exclusion Criteria:~* age \< 18 and \> o = 40 years;~* primary ovarian failure or women known as poor responders (i.e. requiring more than 300 IU of FSH as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an E2 serum concentration \< 3'000 pmol/L);~* ovarian cysts \> 20 mm, or enlargement not due to polycystic ovarian syndrome;~* patients affected by pathologies associated with any contraindication of being pregnant;~* hypersensitivity to the study medication;~* any bleeding since stimulation;~* uncontrolled thyroid or adrenal dysfunction;~* neoplasias;~* severe impairment of the renal and/or hepatic functions;~* use of concomitant medication that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents);~* more than 18 days of FSH stimulation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).